Type 1 diabetes intervention trials 2007: Where are we and where are we going?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 4, 2007, Pages 283-287

  Haller, Michael J ^a   Gottlieb, Peter A ^b   Schatz, Desmond A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Combination therapy; Intervention; Type 1 diabetes

Indexed keywords

AZATHIOPRINE; BCG VACCINE; C PEPTIDE; CD20 ANTIBODY; CD3 ANTIBODY; COLECALCIFEROL; CYCLOSPORIN; DACLIZUMAB; DOCOSAHEXAENOIC ACID; GLUTAMATE DECARBOXYLASE 65; HEAT SHOCK PROTEIN 60; INSULIN; KETOTIFEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OKT 3; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ACCURACY; AUTOIMMUNE DISEASE; CELL FUNCTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE RELEASE SYNDROME; DIABETIC PATIENT; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTERVENTION STUDY; NONHUMAN; PANCREAS ISLET CELL; PATHOPHYSIOLOGY; PREDICTION; PROPHYLAXIS; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS;

EID: 34447542181     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32825a673b     Document Type: Review

References (20)

1. Atkinson MA. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease? Diabetes 2005; 54:1253-1263.
2. Staeva-Vieira T, Peakman M, Von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007; 148:17-31. This excellent review provides an in-depth discussion of nearly every current immunotherapy in clinical trial for T1D.
3. Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am 2005; 52:1553-1578.
4. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358:221-229.
5. Silverstein J, Maclaren N, Riley W, et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988; 319:599-604.
6. Bougneres PF, Carel JC, Castano L, et al. [Cyclosporin and childhood diabetes: preliminary findings of the Saint Vincent de Paul trial]. Journ Annu Diabetol Hotel Dieu 1987: 181-186.
7. Carel JC, Boitard C, Eisenbarth G, et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pretype 1 diabetic children. J Autoimmun 1996; 9:739-745.
8. Eisenbarth GS, Srikanta S, Jackson R, et al. Antithymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985; 2:271-276.
9. Gale EAM. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363:925-931.
10. Bohmer KP, Kolb H, Kuglin B, et al. Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen. Diabetes Care 1994; 17:138-141.
11. Huppmann M, Baumgarten A, Ziegler AG, Bonifacio E. Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care 2005; 28:1204-1206.
12. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial - Type 1. Diabetes Care 2005; 28:1068-1076.
13. Kupila A, Sipila J, Keskinen P, et al. Intranasally administered insulin intended for prevention of type 1 diabetes - a safety study in healthy adults. Diabetes Metab Res Rev 2003; 19:415-420.
14. Harrison LC, Honeyman MC, Steele CE, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27:2348-2355.
15. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19:238-246.
16. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358:1749-1753.
17. Elias D, Avron A, Tamir M, Raz I. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann N Y Acad Sci 2006; 1079:340-344. This paper documents the potential of DiaPep227 as an immunomodulatory therapy for T1D.
18. Lazar L, Ofan R, Weintrob N, et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2006; 23:286-291.
19. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-2608.
20. Haller MJ, Schatz DA. CD3-antibody therapy in new-onset type 1 diabetes mellitus. N Engl J Med 2005; 353:2086-2087; author reply 2086-2087.